Property:RefDocPart
From GxPlex
Article, annex, or section this reference covers.
I
U
I
II A. 3. +
II B.
Serious Adverse Event or Adverse Drug Reaction +
II B.
Serious/Severe +
U
USA Informed Consent - FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023 II. Advertising-001 +
II. Advertising +
USA Informed Consent - FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023 II. Advertising-002 +
II. Advertising +
USA Informed Consent - FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023 II. Introduction +
II. Introduction +
I
U
USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 III - IV. +
III - IV. +
III 2. +
III 4. +
I
III A. 1. +
III A. 2. +
U
USA FDA Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs — Improving Human Subject Protection Jan-2009 III A. ; IV. +
III A. ; IV. +
I
III B. - III C. +
